BioCentury | May 9, 2016
Company News

Acerus Pharmaceuticals, Aytu deal

...Acerus (formerly Trimel Pharmaceuticals Corp. ) granted Aytu exclusive, U.S. marketing rights to testosterone replacement therapy Natesto testosterone...
BioCentury | Jul 14, 2015
Company News

Management tracks

...at US Oncology Inc. , which was acquired by McKesson Corp. (NYSE:MCK). Drug delivery company Trimel Pharmaceuticals Corp....
BioCentury | Apr 13, 2015
Company News

Endo sales and marketing update

...$199 for one dispenser. Last year, Endo acquired U.S. and Mexican rights to Natesto from Trimel Pharmaceuticals Corp....
BioCentury | Feb 9, 2015
Clinical News

Natesto regulatory update

...from Trimel to commercialize Natesto in the U.S. and Mexico (see BioCentury, Dec. 15, 2014). Trimel Pharmaceuticals Corp....
BioCentury | Dec 15, 2014
Company News

Trimel Pharmaceuticals, Endo deal

...collaborate with Trimel on clinical development and regulatory activities for Natesto (see BioCentury, June 2). Trimel Pharmaceuticals Corp....
BioCentury | Aug 11, 2014
Strategy

Profusion of exclusions

...Osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, tendonitis, bursitis and acute gout ü Natesto testosterone Trimel Pharmaceuticals Corp....
BioCentury | Aug 4, 2014
Clinical News

Tefina: Phase II data

...after it completes its analysis of the data, but did not disclose a time frame. Trimel Pharmaceuticals Corp....
BioCentury | Jul 14, 2014
Finance

2Q Stock Wrap-Up: Large and in charge

...NYSE:GSK) EC approves Anoro umeclidinium/vilanterol as a once-daily maintenance bronchodilator to relieve symptoms in COPD Trimel Pharmaceuticals Corp....
BioCentury | Jun 2, 2014
Finance

Highlights of weekly biotech stock moves

...in chronic kidney disease (CKD) patients receiving hemodialysis. The PDUFA date is Jan. 24, 2015. Trimel Pharmaceuticals Corp....
BioCentury | Jun 2, 2014
Clinical News

Natesto regulatory update

...the bioadhesive intranasal gel formulation of testosterone to reflect thrice-daily dosing (see BioCentury, Jan. 20). Trimel Pharmaceuticals Corp....
Items per page:
1 - 10 of 50
BioCentury | May 9, 2016
Company News

Acerus Pharmaceuticals, Aytu deal

...Acerus (formerly Trimel Pharmaceuticals Corp. ) granted Aytu exclusive, U.S. marketing rights to testosterone replacement therapy Natesto testosterone...
BioCentury | Jul 14, 2015
Company News

Management tracks

...at US Oncology Inc. , which was acquired by McKesson Corp. (NYSE:MCK). Drug delivery company Trimel Pharmaceuticals Corp....
BioCentury | Apr 13, 2015
Company News

Endo sales and marketing update

...$199 for one dispenser. Last year, Endo acquired U.S. and Mexican rights to Natesto from Trimel Pharmaceuticals Corp....
BioCentury | Feb 9, 2015
Clinical News

Natesto regulatory update

...from Trimel to commercialize Natesto in the U.S. and Mexico (see BioCentury, Dec. 15, 2014). Trimel Pharmaceuticals Corp....
BioCentury | Dec 15, 2014
Company News

Trimel Pharmaceuticals, Endo deal

...collaborate with Trimel on clinical development and regulatory activities for Natesto (see BioCentury, June 2). Trimel Pharmaceuticals Corp....
BioCentury | Aug 11, 2014
Strategy

Profusion of exclusions

...Osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, tendonitis, bursitis and acute gout ü Natesto testosterone Trimel Pharmaceuticals Corp....
BioCentury | Aug 4, 2014
Clinical News

Tefina: Phase II data

...after it completes its analysis of the data, but did not disclose a time frame. Trimel Pharmaceuticals Corp....
BioCentury | Jul 14, 2014
Finance

2Q Stock Wrap-Up: Large and in charge

...NYSE:GSK) EC approves Anoro umeclidinium/vilanterol as a once-daily maintenance bronchodilator to relieve symptoms in COPD Trimel Pharmaceuticals Corp....
BioCentury | Jun 2, 2014
Finance

Highlights of weekly biotech stock moves

...in chronic kidney disease (CKD) patients receiving hemodialysis. The PDUFA date is Jan. 24, 2015. Trimel Pharmaceuticals Corp....
BioCentury | Jun 2, 2014
Clinical News

Natesto regulatory update

...the bioadhesive intranasal gel formulation of testosterone to reflect thrice-daily dosing (see BioCentury, Jan. 20). Trimel Pharmaceuticals Corp....
Items per page:
1 - 10 of 50